Investment Committee Summary
| Rating | SELL |
| Internal 5-tier | SELL |
| Classification · conviction | cyclical compounder · medium |
| Evidence | 6/8 load-bearing inputs sourced — missing: Capex, Peer multiples |
| Triangulated fair value | $77.86 (-29% vs spot · triangulated FV) |
| 12-mo scenario PWEV | $88.74 (-19% vs spot · 12m PWEV) |
| Next catalyst | 2026-11-04 — Quarterly earnings |
| Primary thesis-break | FY revenue ($B) < 1.93 (the next 2 reported fiscal years) |
Decision detail — rating tables & Research OS strip
Rating: SELL
Internal 5-tier: SELL · cyclical compounder · analyst conviction: medium
| Metric | Value |
|---|---|
| Current Price | $110 |
| Triangulated Fair Value | $77.86 (-29% vs spot · triangulated FV) |
| 12-mo Scenario PWEV | $88.74 (-19% vs spot · 12m PWEV) |
| Market Cap | $6B |
| 52-Week Range | $48.82–$142 (intraday high and low over the trailing 52 weeks of the stock's own daily bars) |
EPS basis for the forward P/E and all scenario multiples: consensus forward EPS (broker-adjusted, non-GAAP).
Methodology: Valuation triangulated across three weighted anchors — an intrinsic DCF, a scenario-weighted PWEV and a Monte Carlo median (Student-t + regime switching). Anchors are blended at fixed declared weights, each counted separately; the Monte Carlo, the scenario PWEV and the DCF's exit-multiple terminal all rest on the same base multiple, so where they agree it is partly by construction — not independent corroboration. Figures reconciled to Alpha Vantage 2026-10-12. Each chart below sits with the part of the thesis it evidences.
General research, published identically to every reader. Not personal financial advice. Figures as of the analysis date; verify before acting.
Decision Support — Research OS jump to detail ↓
| Research conviction | Exp. return (1y) | Rules stance | Next catalyst |
|---|---|---|---|
| 48.1/100 (24th pct) | -18% 1yr expected | Hold | 22d — Quarterly earnings |
Research rating: SELL · Tactical / decision-rule stance: Hold — the stance is what the model's 6 machine-checked decision rules read on this name, held by hysteresis against the last published stance; the rating is the valuation verdict. They may diverge; the rules are set out in the Decision Rules section below.
Full breakdown — conviction components, probability-return distribution, decision rules, factor & portfolio interaction and the catalyst timeline — in the Decision Support sections below. Model output for research; not personal financial advice.
📎 Download the full model (Excel) — DCF line items, scenarios, sensitivity, assumptions, and extended fundamentals.
Recommendation: SELL
Defensive: rating SELL; triangulated fair value $77.86 (-29% vs spot) — the risk/reward is skewed to the downside on Gross Margin. The debate is Gross Margin — a fundamental call.
Investment Thesis
At $110 (13 October 2026) e.l.f. Beauty is priced as a branded beauty franchise with genuine growth optionality rather than as a commodity personal-care manufacturer. The single reporting line is branded household and personal care, where the economics are organic volume, pricing power against input costs, and the mix benefit that comes with premium innovation and international expansion; the operating margin currently runs near 10% (reported GAAP, TTM to Jun 2026). The engine's mid-cycle path, pricing-led organic growth, carries the largest single weight, and the twelve-month target of $88.74 and probability-weighted expected value of $88.74 both sit modestly below the current quote. Triangulation lands at $77.86, leaving the shares trading rich to that anchor (-29%), which is why the rating is SELL: the growth is real, but the price already reflects a good deal of it. The balance sheet carries net debt of ~$0.6B, and capex takes only a low-single-digit share of revenue: growth is funded through working capital and marketing, not fixed assets. The shares have travelled an exceptionally wide 52-week range, evidence the market has no settled view of the terminal margin. The single most damaging risk is that the brand premium proves rented rather than owned: if value competitors and retailer labels erode the pricing that supports the margin, earnings and the multiple compress together and the structural path sits below the 52-week low.
Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.
The dashboard below is the whole argument on one page: spot ($110) against each valuation anchor, the scenario tree, technicals and the options-implied move.
Anti-Thesis (The Real Bear Case)
The highest-probability bear is the Structural — Private-Label / Brand Erosion path, and its mechanism is pricing rather than demand. Value-oriented beauty is a category with low structural barriers: formulation is outsourced, shelf space is rented from a handful of mass retailers, and the consumer who traded into the brand for price can trade out again just as easily. If retailers expand their own labels, or competing value brands buy shelf and marketing share, organic volume growth slows while promotional intensity rises. The operating margin then compresses from the current level toward the category norm, and it does so without any collapse in category demand, because the mechanism is the loss of the pricing spread rather than the loss of the customer. Since the market capitalises this business on growth rather than on assets, the multiple de-rates at the same time as the earnings fall and the two compound. The width of the 52-week range shows how fast that repricing can happen, the structural path sits below the 52-week low, and a balance sheet at net debt of ~$0.6B provides only a thin buffer.
Key Debate
Gross Margin explains 60% of Monte Carlo outcome variance — the single variable that decides which side is right.
What the Market Is Pricing In
At the current price, the market pays 30.3× consensus forward EPS, vs the house DCF terminal 21.0×. The house DCF sits 37% below spot, so the market is pricing in more than the house case — roughly 4.1pp of revenue CAGR.
Variant perception: the house view is below-consensus, and the thesis is primarily growth-driven.
| Metric | Consensus | House | Importance |
|---|---|---|---|
| Revenue | 2.0 | 2.1 | High |
| EPS | 3.6 | 3.6 | Medium |
| Target price | 104.1 | 88.7 | Medium |
Historical-range cross-check: 52-week range $48.82–$142, centre $83.10 (-24% vs spot); spot sits at the 66th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.
Scenario Analysis
The scenario tree spans a structural 'Structural — Private-Label / Brand Erosion' downside ($41.50) to a 'Bull — Defensive Re-Rate' bull case ($144); the probability-weighted blend (PWEV $88.74) is -19% versus spot.
| Scenario | Probability | Target | Return vs spot |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $41.50 | -62% |
| Consumer / Input Recession | 18% | $74.71 | -32% |
| Base — Pricing-Led Organic Growth | 34% | $96.67 | -12% |
| Growth — Premium Innovation + EM | 20% | $122 | +11% |
| Bull — Defensive Re-Rate | 8% | $144 | +31% |
| Probability-Weighted (PWEV, after SBC dilution) | — | $88.74 | -19% |
SBC charge: scenario targets are gross per-share prices; the PWEV is reduced by one year of stock-based-compensation dilution (2.0% of shares, on SBC ≈ 5% of revenue), trimming the gross PWEV of $90.51 to $88.74 (-2.0%). SBC is charged once, as dilution — never also deducted from FCF.
Scenario rationale — the driver path behind every target:
- Structural — Private-Label / Brand Erosion (20%, $41.50). Structural impairment — private-label / brand erosion: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
- Consumer / Input Recession (18%, $74.71). Cyclical downturn — branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) weakens for 1–2 years before normalising.
- Base — Pricing-Led Organic Growth (34%, $96.67). Mid-cycle — normalised branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail); disciplined capital allocation; steady returns.
- Growth — Premium Innovation + EM (20%, $122). Upside — premium innovation + emerging markets lifts earnings above mid-cycle; the multiple expands modestly.
- Bull — Defensive Re-Rate (8%, $144). Upside tail — sustained tight conditions or a structural re-rate on premium innovation + emerging markets.
Valuation Triangulation
Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the scenario PWEV, any DCF's exit-multiple terminal and any peer re-rate key off a market multiple, so they are not independent; only a DCF's explicit-period cash flows are multiple-free, and its terminal usually carries most of its value. The discipline is to read the spread, not to treat three numbers as three independent votes.
| Method | Basis | Fair Value | vs Spot | Weight in this name's blend |
|---|---|---|---|---|
| Monte Carlo median (Student-t + regime) | multiple | $80.01 | -27% | 20% (declared 15%) |
| Scenario PWEV | multiple | $88.74 | -19% | 33% (declared 25%) |
| DCF (5-year + exit-multiple terminal) | cash flow + terminal × | $69.16 | -37% | 47% (declared 35%) |
| Triangulated (weighted) | — | $77.86 | -29% | 100% |
The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way. The company-lever row in the Sensitivity section is an illustrative EBIT × multiple value, not a sum-of-parts anchor.
Monte Carlo — the outcome distribution
10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $80.01 and 26% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (60% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.
DCF — explicit-period cash flows with an exit-multiple terminal
A 5-year cash-flow path discounted at a WACC of 7.5%, plus a terminal value of final-year FCF × 21.0x — a terminal multiple equal to 0.85 × the base multiple that the Monte Carlo and the scenario tree also use → $69.16. The terminal value is 80% of enterprise value, so this anchor moves with the multiple assumption. The heaviest anchor in this blend (47%); because its terminal is a market multiple, it is not independent of the multiple-driven anchors.
Peer benchmarking — relative value
Against the peer cohort the engine carries no peer-implied price for this name — no P/E-implied price is carried for this name, and no revenue basis either — so the cohort is shown for context only. A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.
Across all anchors the spread is 24% of the median — moderate (healthy method disagreement — read the blend with care).
Sensitivity
DCF/share — WACC × terminal multiple
| WACC ＼ Term× | 14.7x | 17.8x | 21.0x | 24.1x | 27.3x |
|---|---|---|---|---|---|
| 5.5% | $55.42 | $65.71 | $76.34 | $86.63 | $97.25 |
| 6.5% | $52.70 | $62.52 | $72.65 | $82.47 | $92.60 |
| 7.5% | $50.12 | $59.49 | $69.16 | $78.53 | $88.20 |
| 8.5% | $47.67 | $56.62 | $65.85 | $74.80 | $84.03 |
| 9.5% | $45.35 | $53.90 | $62.72 | $71.26 | $80.09 |
DCF/share — revenue CAGR Δ × model op-margin Δ (Δ applied to the DCF's house margin path)
| CAGRΔ ＼ MgnΔ | -3.0pp | -1.5pp | +0.0pp | +1.5pp | +3.0pp |
|---|---|---|---|---|---|
| -3.0pp | $44.03 | $52.21 | $60.38 | $68.55 | $76.73 |
| -1.5pp | $47.17 | $55.91 | $64.65 | $73.40 | $82.14 |
| +0.0pp | $50.47 | $59.82 | $69.16 | $78.50 | $87.85 |
| +1.5pp | $53.94 | $63.92 | $73.90 | $83.89 | $93.87 |
| +3.0pp | $57.59 | $68.25 | $78.90 | $89.55 | $100 |
Tornado — DCF/share swing by driver (widest first)
| Driver | Low | High | Swing |
|---|---|---|---|
| Model op margin ±3pp | $50.00 | $88.00 | $37.00 |
| Terminal × ±15% | $60.00 | $79.00 | $19.00 |
| Revenue CAGR ±3pp | $60.00 | $79.00 | $19.00 |
| WACC ±1pp | $66.00 | $73.00 | $7.00 |
| Capex intensity ±15% | $66.00 | $73.00 | $7.00 |
Company lever — value at the base multiple vs Household & Personal Care multiple (base 25.0x)
| Multiple | 17.5x | 21.2x | 25.0x | 28.7x | 32.5x |
|---|---|---|---|---|---|
| Value at the base multiple (EBIT × multiple; illustrative, not a blend anchor) | $1.00 | $4.00 | $7.00 | $9.00 | $12.00 |
Illustrative: segment EBIT × multiple, plus net cash, over basic shares — it does not enter the triangulated fair value.
Risk / Reward & Margin of Safety
| Metric | Value |
|---|---|
| Upside to triangulated FV (FV ÷ price − 1) | $77.86 (-29% vs spot · triangulated FV) |
| Downside to lowest scenario (Structural — Private-Label / Brand Erosion) | $41.50 (-62% vs spot · bear scenario) |
| Reward-to-risk ratio | withheld — the triangulated FV is at or below spot, so there is no reward leg to divide by the risk leg |
| Discount to fair value (1 − price ÷ FV) | -41% |
| P(price > spot) — Monte Carlo | 26% |
That ratio is (triangulated FV ÷ price − 1) ÷ (1 − 'Structural — Private-Label / Brand Erosion' target ÷ price). 'Structural — Private-Label / Brand Erosion' ($41.50, probability 20%) is the lowest-target scenario in the tree, taken gross of SBC dilution. With a leg missing the ratio is withheld rather than computed from a magnitude. Bull case (Bull — Defensive Re-Rate): $144.
Company Overview & Business Model
ELF Beauty Inc — CONSUMER DEFENSIVE · HOUSEHOLD & PERSONAL PRODUCTS. elf Beauty, Inc., offers skin care and cosmetic products under the elf, W3LL PEOPLE and Keys Soulcare brand names worldwide. The company is headquartered in Oakland, California.
Company description as supplied by Alpha Vantage; not checked against the company's filings.
How it makes money.
| Segment | Rev mix | Growth | Model op margin† | Key driver |
|---|---|---|---|---|
| Household & Personal Care | 100% | +4% | 12% | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
† Model margin = gross margin − the opex ratio calibrated so the Monte Carlo median EPS meets the EPS target; it is not a reported operating margin.
Reported operating margin (GAAP): 8.0% for the fiscal year ended 2026-03-31; 10.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Revenue-Segment Breakdown
The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)
| Segment | Revenue | Mix | Growth | Model op margin† | Model EBIT | Multiple | Capex % | Tag |
|---|---|---|---|---|---|---|---|---|
| Household & Personal Care | $0.3B | 100% | 4% | 12% | $0.0B | 25.0x | 3% | ESTIMATE |
| † Model EBIT = revenue × the model margin, i.e. gross margin less the opex ratio the calibration solved for to meet the EPS target — not the company's reported operating income. |
For comparison, the company's reported GAAP operating margin was 8.0% for the fiscal year ended 2026-03-31; 10.5% TTM to 2026-06-30 (Alpha Vantage INCOME_STATEMENT).
Named Exposures
Demand & pricing cycle (FACT/ESTIMATE)
| Dimension | Assessment |
|---|---|
| driver | branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail) |
| net_debt_or_cash_b | -0.58 |
Capital intensity & shareholder returns (ESTIMATE)
| Dimension | Assessment |
|---|---|
| capex_pct_revenue | 0.03 |
| div_yield | — |
Structural risk vs optionality (INFERENCE)
| Dimension | Assessment |
|---|---|
| downside | private-label / brand erosion |
| upside | premium innovation + emerging markets |
Industry Context — Consumer Staples — Household
This name sits in the Consumer Staples — Household cluster as a household & personal care name. branded HPC pricing power + organic volume + input costs (beauty: China/travel-retail). Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.
Value chain: REYN (household & personal care) · ELF (household & personal care)
| Shared state | Capex path | House view | This name implies |
|---|---|---|---|
| Structural — Private-Label / Brand Erosion | not stated | 38% | 38% |
| Mid-Cycle — Pricing-Led Organic Growth | not stated | 34% | 34% |
| Upside — Premium Innovation / EM | not stated | 28% | 28% |
Mapping note: name-level 'Structural — Private-Label / Brand Erosion' (20%) + 'Consumer / Input Recession' (18%) map to cluster Structural — Private-Label / Brand Erosion (38%); name-level 'Growth — Premium Innovation + EM' (20%) + 'Bull — Defensive Re-Rate' (8%) map to cluster Upside — Premium Innovation / EM (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.
On the cluster's key downside — Structural — Private-Label / Brand Erosion — this name implies 38% vs the cluster house view of 38% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.
Structure: Shared State — The Consumer Staples — Household cycle is the shared macro driver. Driver — branded HPC pricing power + organic volume + input costs. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).
Balance Sheet & Liquidity
| Metric | Value |
|---|---|
| Net debt | $0.6B — levered |
| Net debt / EBITDA | 2.99x |
| Interest coverage (EBIT / interest) | 2.0x |
| Current ratio | 2.35x |
| Lease obligations | $0.1B |
| Cash & ST investments | $0.3B |
Balance-sheet data as of 2026-03-31 (Alpha Vantage).
Capital Allocation
| Metric | Value |
|---|---|
| Free cash flow | $0.2B |
| Buybacks / dividends | $0.1B / $0.0B |
| Total shareholder yield | 0.8% |
| Payout as % of FCF | 26.3% |
| Reinvestment (capex / OCF) | 10.3% |
| SBC as % of FCF | 45.8% |
| Allocation stance | reinvesting |
Free-Cash-Flow Quality
| Metric | Value |
|---|---|
| FCF margin | 10.8% |
| FCF conversion (FCF / net income) | 730.8% |
| FCF yield | 3.1% |
| Capex intensity (capex / revenue) | 1.2% |
| FCF − SBC (diagnostic) | $0.1B |
Accounting quality: SBC 5% of revenue.
Earnings-Call Disconfirmation & Sentiment
Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.
Management vs analyst tone (2026Q3): management +0.50 vs analyst floor +0.24 → delta +0.26 (n=22 mgmt / 12 Q&A; 19th pctile across the S&P book, z -1.0).
Flag: TYPICAL — management-vs-analyst tone within the normal cross-sectional range.
| Quarter | Mgmt | Analyst | Delta |
|---|---|---|---|
| 2026Q3 | +0.50 | +0.24 | +0.26 |
| 2026Q2 | +0.55 | +0.00 | +0.55 |
| 2026Q1 | +0.50 | +0.14 | +0.36 |
| 2025Q4 | +0.57 | +0.09 | +0.48 |
News (last 365d, 467 articles): avg ticker sentiment +0.13 (bullish 29% / bearish 10%)
Consensus & Market Expectations
| Reference | Value |
|---|---|
| Street target (mean) | $104 (-5% vs spot · street) |
| House target | $88.74 (-14.7% vs street) |
| Sell-side coverage | 18 analysts (SB 1 / B 11 / H 6 / S 0 / SS 0; net score 0.36) |
| Consensus FY EPS | $3.62 (reference only — house values on EV/EBITDA) |
| Consensus FY revenue | $2.0B; house above (+6.7%) |
_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.
Catalyst Calendar
- 2026-11-04 (~23d) — Quarterly earnings — est. EPS $0.34 (AV EARNINGS_CALENDAR)
Forecast Track Record
- EPS surprise: beat 75% of the last 8 quarters; average surprise +43.1%.
Catalyst Timeline
5 catalysts in the next 90 days (of 12 tracked). Importance 1–3; confidence 0–1.
| When | Catalyst | Type | Importance | Confidence |
|---|---|---|---|---|
| 2026-10-14 (in 1d) | September CPI | macro | ●● | 0.8 |
| 2026-10-28 (in 15d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2026-11-04 (in 22d) | Quarterly earnings | earnings | ●●● | 0.95 |
| 2026-12-09 (in 57d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2026-12-18 (in 66d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-01-27 (in 106d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-03-17 (in 155d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-03-19 (in 157d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-04-28 (in 197d) | FOMC rate decision + press conference | macro | ●● | 0.8 |
| 2027-06-09 (in 239d) | FOMC rate decision + SEP dot plot | macro | ●● | 0.8 |
| 2027-06-18 (in 248d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
| 2027-09-17 (in 339d) | Quarterly options-expiry cluster (3rd Friday) | opex_cluster | ● | 1.0 |
_Sources: extended.catalysts, data/catalysts/
Decision Rules (Machine-Checked)
Stance: Hold — 0 bullish / 1 bearish / 1 caution rules triggered of 5 evaluable (1 lacked data).
| Rule | Condition | Observed | Triggered |
|---|---|---|---|
| R1-valuation-stretch | expected return vs fair value < -12 (upside_pct) |
-19.29 | YES |
| R2-valuation-opportunity | expected return vs fair value > 15 (upside_pct) |
-19.29 | no |
| R3-street-revisions | street net rating stance < -0.25 (extended.consensus.street_score) |
0.36 | no |
| R4-earnings-quality | cash conversion of earnings < 80 (extended.accounting_quality.cash_conversion_pct) |
no data | — |
| R5-technical-breakdown | price vs 200-day SMA < 0.85 (technicals.sma_200) |
1.39 | no |
| R6-vol-regime-shift | IV/RV vol-risk premium > 1.4 (options_overlay.iv_rv) |
1.66 | YES |
Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is what the model's own rules read on this name; it does not modify the published research rating, and it is not personal financial advice.
Reasons the Thesis Could Fail (Falsifiable)
Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:
- FY revenue ($B) < 1.93 (the next 2 reported fiscal years). (rationale withheld pending re-authoring — frozen figure or verdict)
- Probability-weighted fair value (PWEV) at the next re-run < 109.94 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)
- Share price (close) < 41.5 (5 consecutive sessions). (rationale withheld pending re-authoring — frozen figure or verdict)
Fact / Inference / Speculation
- FACT: Spot $110; 52-week range $48.82–$142; engine rating SELL; house target $88.74 (-19%). (source: Alpha Vantage 2026-10-12, 13 October 2026)
- INFERENCE: Triangulated FV $77.86 (-29% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the DCF anchor sits below the multiple-discipline core.
- SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.
Conviction Score
Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.
48.1/100 (confidence band 37.7–58.5), 24th percentile of 928 covered names (as of 2026-10-12). Weighted composite under config ros-1.21.0 — every component and its inputs below.
| Component | Score (0–100) | Weight | Inputs |
|---|---|---|---|
| business quality | 36 | 15% | extended.fcf_quality.fcf_margin_pct, extended.balance_sheet.net_debt_to_ebitda, extended.accounting_quality.cash_conversion_pct |
| financial strength | 26 | 10% | extended.balance_sheet.net_debt_to_ebitda, extended.balance_sheet.interest_coverage |
| valuation | 31 | 15% | upside_pct |
| growth | 63 | 10% | reconciliation.ttm_revenue_billions, reconciliation.fy_guide_revenue_billions |
| earnings visibility | 75 | 10% | extended.forecast_accuracy.eps_surprise.beat_rate_pct |
| moat | 45 | 10% | |
| technical trend (heuristic — no validation record; weight change reserved for AM-060) | 90 | 10% | technicals.rsi, technicals.sma_50, technicals.sma_200 |
| macro tailwinds | 40 | 10% | industry_context.scenario_states |
| risk profile | 42 | 10% | monte_carlo.prob_above_current, monte_carlo.p10, monte_carlo.p90, monte_carlo.median |
Score history: 52.5 → 52.4 → 52.5 → 52.3 → 52.3 → 52.1 → 51.6 → 51.6.
Probability-Weighted Return Profile
Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.
| Scenario | Probability | Target | Total return | Contribution |
|---|---|---|---|---|
| Structural — Private-Label / Brand Erosion | 20% | $41.50 | -62.3% | -12.4pp |
| Consumer / Input Recession | 18% | $74.71 | -32.0% | -5.8pp |
| Base — Pricing-Led Organic Growth | 34% | $96.67 | -12.1% | -4.1pp |
| Growth — Premium Innovation + EM | 20% | $122 | +11.0% | +2.2pp |
| Bull — Defensive Re-Rate | 8% | $144 | +30.6% | +2.5pp |
| Aggregate | Value |
|---|---|
| Expected return (gross, 1y) | -17.7% |
| Expected return net of SBC dilution | -19.3% |
| Outcome dispersion (σ, from MC p10–p90) | 38.9% |
| Expected Sharpe (rf 4%) | -0.56 |
| Downside expectation (prob-weighted loss branches) | -22.3% |
The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.
Expected Alpha
Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).
| Component | Value |
|---|---|
| Expected return (gross, 1y) | -17.7% |
| Risk-free rate | 4.49% (1y proxy (3m/2y midpoint; AV lacks a 1y tenor), as of 2026-10-08) |
| Beta (shrunk, 1y vs SPY) | 1.47 (as of 2026-10-12) |
| Equity risk premium | 4.5% |
| Size/liquidity premium | +100bp |
| Required return | 12.1% |
| Expected alpha | -29.8% |
| Alpha per unit risk (EA/σ) | -0.77 |
A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.
Probability Cross-Checks
Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.
| Cross-check | Ours | Comparator | Reading |
|---|---|---|---|
| Scenario spread vs options market | 28.2% (1σ) | 53.7% implied | broadly consistent with the market's implied uncertainty |
| Mass above spot: scenarios vs our own MC | 28.0% | 26.4% | the two expressions of our own view agree |
| Realised scenario frequency | 59 dated anchors | — | 59 dated anchors available; realised-vs-prior comparison is now meaningful. |
Authored set: 5 scenarios, probabilities summing to 1.0, mean target $90.51.
Factor Exposures
Cross-sectional percentiles over 928 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.
| Style | Percentile | Theme | Percentile | |
|---|---|---|---|---|
| Growth | 95 | AI | 83 | |
| Value | 14 | Cloud | 87 | |
| Quality | 24 | Semis | 81 | |
| Momentum | 18 | Consumer | 99 | |
| Low-Vol | 8 | Rates | 25 | |
| USD | 39 | |||
| Energy | 8 |
Market interaction: correlation vs SPY +0.36, vs QQQ +0.35 (trailing ~1y daily returns).
Rating Bridge
Rating = SELL because:
- Probability-weighted scenario value implies -19% vs spot
- Monte Carlo median implies -27% vs spot
- DCF fair value (exit-multiple terminal) implies -37% vs spot
- Bear case (Structural — Private-Label / Brand Erosion) downside is -62% vs spot
- Net: the valuation anchor itself sits 29.2% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.
Model Appendix
DCF — line items
| Year | Revenue | Op income (house path) | − Capex | + D&A | FCF | PV(FCF) |
|---|---|---|---|---|---|---|
| FY+1 | $2B | $0B | $0B | $0B | $0B | $0B |
| FY+2 | $2B | $0B | $0B | $0B | $0B | $0B |
| FY+3 | $2B | $0B | $0B | $0B | $0B | $0B |
| FY+4 | $2B | $0B | $0B | $0B | $0B | $0B |
| FY+5 | $2B | $0B | $0B | $0B | $0B | $0B |
| Terminal | — | — | — | — | $0B × 21.0x | $3B |
FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 3% of revenue, weighted from the segments) — not a single conversion fudge.
WACC 7.5% · Σ PV(FCF) $1B + PV(terminal) $3B = EV $4B; − net debt $0.6B → equity $4B ÷ diluted shares $0.06B = $69.16/share (exit-multiple terminal).
- Gordon terminal → $67.65/share — a single-point perpetual-growth cross-check at g = 2.5% (one growth rate, not a range; it is not in the blend).
- Incremental ROIC on the forecast capex ≈ 13% vs WACC 7.5% → above WACC — the build is value-creative.
Weighted fair-value math
| Anchor | Value | Weight | Contribution |
|---|---|---|---|
| DCF | $69.16 | 47% | $32.27 |
| Scenario PWEV | $88.74 | 33% | $29.58 |
| Monte Carlo median | $80.01 | 20% | $16.00 |
| Triangulated | — | 100% | $77.86 |
Model Calibration Caveats
Raised by the model's own checks on its run of 13 October 2026 (prices as of 2026-10-12). They concern how the model was calibrated, not the company; read the figures they touch with them in mind.
- The Monte Carlo gives only a 26% probability of the price finishing above today's; the house treats readings under 30% as a sign the downside assumptions may be too severe.
Assumption Register
| Assumption | Value | Used in | Source |
|---|---|---|---|
| WACC | 7.5% | DCF discount rate | estimate (CAPM) |
| Terminal multiple | 21× | DCF exit value | house rule (0.85 × base multiple) |
| Terminal growth | 2.5% | Gordon cross-check (single point) | estimate |
| SBC dilution | 2.0%/yr | PWEV, MC, DCF (charged once) | estimate (from SBC/rev) |
| EPS basis | consensus forward EPS (broker-adjusted, non-GAAP) | all forward P/E & scenario multiples | definition |
Sensitivity-ranked drivers (widest fair-value swing first): Model op margin ±3pp (37.0); Terminal × ±15% (19.0); Revenue CAGR ±3pp (19.0); WACC ±1pp (7.0); Capex intensity ±15% (7.0).
Inputs, Sources & Confidence
Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)
| Input | Value | Type | Source | Confidence | Used in |
|---|---|---|---|---|---|
| Revenue TTM | $1.76B | reported fact | 10-K/10-Q via AV | High | Forecast base, EV/Rev |
| FY+1 guided revenue | $2.1B | company guidance | Company guidance | Medium | Forecast, SoP |
| FY+1 guided EPS | $3.6205 | company guidance | Company guidance | Medium | Forward P/E, scenarios |
| Consensus FY EPS | $3.6241 | consensus estimate | Sell-side consensus via AV | Medium | Variant perception |
| Diluted shares | 0.055B | reported fact | 10-K via AV | High | Market cap, per-share |
| Net debt / cash | $0.627B | reported fact | Balance sheet via AV | High | EV, DCF equity bridge |
| WACC | 7.5% | house estimate | CAPM (beta/rf) | Medium | DCF discount rate |
| Terminal multiple | 21× | house estimate | House rule: 0.85 × the base multiple (shared with the Monte Carlo) | Medium | DCF exit value |
| Terminal growth | 2.5% | house estimate | Long-run GDP+ | Medium | Gordon cross-check (single point, not in the blend) |
| SBC dilution | 2.0%/yr | house estimate | From SBC/revenue | Medium | PWEV, MC, DCF (charged once) |
Research Provenance
| Field | Value |
|---|---|
| Quantitative engine | mch_stock_engine v2.0 |
| Research OS config | ros-1.21.0 |
| Analysis as-of | 2026-10-13 (prices 2026-10-12) |
| Narrative authorship | claude-opus-5 · Claude Code, supervised, drafted 2026-08-16 |
| Human review | Marinus 2026-08-16 |
| Evidence | 6/8 load-bearing inputs sourced; 10/14 mandated claims cited |
| QA | scanned post-emit by the document-QA layer; the publication label (Draft / Research / Decision-level) is stamped on the published page, not authored here |
Load-Bearing Assumptions
The stock-based-compensation charge sits on a step boundary. SBC is 5.31% of filed revenue — 0.31pp above the 5% threshold where the authoring rule changes step. The 2.0%/yr dilution it carries reduces the published target by about 2.0%; the other side of that threshold would carry roughly 1.5%/yr. This input is a step, not a measurement, and a modest revision to either the SBC or the revenue figure would move it.
DCF: WACC 7.5%, terminal multiple 21×, FY+5 revenue $2B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.
Appendix & audit trail — source log, data provenance, disclosures
Source Log
| Source | Type | Date | Used for | Reference |
|---|---|---|---|---|
| Alpha Vantage — GLOBAL_QUOTE / OVERVIEW | market data | 2026-10-12 | Price, market cap, EV, forward P/E | Alpha Vantage 2026-10-12 |
| MCH engine — trailing 52 weeks of daily bars | derived | 2026-10-12 | 52-week range (intraday high and low over the trailing year of the stock's own daily bars) | trailing 52 weeks of own daily bars (intraday high/low, 2025-10-13 to 2026-10-09, 250 sessions) |
| Company income statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Revenue, gross/operating margin, EBIT, interest expense | INCOME_STATEMENT / latest annual |
| Company balance sheet (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Cash, debt, net debt, leases, equity, coverage | BALANCE_SHEET / latest annual |
| Company cash-flow statement (10-K / 10-Q) via Alpha Vantage | reported fact | 2026-10-12 | Operating cash flow, capex, FCF, buybacks, dividends, SBC | CASH_FLOW / latest annual |
| Company earnings releases via Alpha Vantage | reported fact | 2026-10-12 | Reported EPS, surprise history | EARNINGS / quarterly |
| Sell-side consensus via Alpha Vantage | consensus estimate | 2026-10-12 | Forward revenue/EPS consensus, analyst count | EARNINGS_ESTIMATES |
| Earnings calendar via Alpha Vantage | market data | 2026-10-12 | Next earnings date, catalyst timing | EARNINGS_CALENDAR |
| Company guidance | company guidance | 2026-10-12 | FY guided revenue / non-GAAP EPS basis | company guidance / earnings call |
| MCH segment model (from filings & disclosures) | house estimate | 2026-10-12 | Segment revenue and multiple; model margin = gross margin − the calibrated opex ratio (not a reported margin) | company_context (authored, tagged) |
| MCH investment thesis & falsification triggers | house estimate | 2026-10-12 | Thesis, anti-thesis, thesis-break signals | authored §5.3 |
Citation coverage: 10/14 mandated claims sourced. Filing URLs are not available via the market-data provider; company statements are cited as 10-K/10-Q via Alpha Vantage.
Data Sources
- Prices, fundamentals, options chain, earnings — Alpha Vantage.
- Company filings (10-K / 10-Q) — SEC filings via EDGAR.
Disclosures & Limitations
This report is for informational and research purposes only. It is not personal financial advice and does not consider any investor's objectives, financial situation, risk tolerance, tax position, or liquidity needs.
- This report is produced by the MCH Analysis quantitative research engine — valuation, scenarios, Monte Carlo and the decision layer are generated systematically from the disclosed inputs and the archetype/industry driver sets, and reviewed rather than written name-by-name. Every figure reconciles to the appendix and every score exposes its inputs.
- No suitability assessment has been performed for any individual.
- Market data may be delayed or inaccurate; figures are as of the analysis date.
- Model outputs (fair values, targets, scenario probabilities) are estimates and may be wrong.
- Forecasts are uncertain; past performance is not indicative of future returns.
- The author or publisher may hold positions in securities mentioned.
- Users should verify information against primary sources (company filings) before acting.
- Investing involves risk of loss; there is no guarantee any target price is achieved.
- Ratings follow a defined research methodology (12-month expected-return thresholds), not individual circumstances.